A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

@article{Stover2000ASN,
  title={A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis},
  author={C Kendall Stover and Paul Warrener and Donald R. VanDevanter and David R. Sherman and Taraq M. Arain and Mike Langhorne and Scott W Anderson and J. Andrew Towell and Ying Yuan and David Neil McMurray and Barry N. Kreiswirth and Clifton E. Barry and William R. Baker},
  journal={Nature},
  year={2000},
  volume={405},
  pages={962-966}
}
Mycobacterium tuberculosis, which causes tuberculosis, is the greatest single infectious cause of mortality worldwide, killing roughly two million people annually. Estimates indicate that one-third of the world population is infected with latent M. tuberculosis. The synergy between tuberculosis and the AIDS epidemic, and the surge of multidrug-resistant clinical isolates of M. tuberculosis have reaffirmed tuberculosis as a primary public health threat. However, new antitubercular drugs with new… 

Indolcarboxamide Is a Preclinical Candidate for Treating Multidrug-Resistant Tuberculosis

TLDR
The authors found that the molecular target of the indolcarboxamides was MmpL3, a protein that is essential for mycobacterial cell wall biosynthesis and growth, and were efficacious in treating Mtb infections in mouse models of acute and chronic TB with a favorable safety margin.

Nitroimidazopyrazinones with oral activity against tuberculosis and Chagas disease in mouse models of infection

TLDR
Derby derivatives with monocyclic side chains are selective against Mycobacterium tuberculosis, the causative agent of tuberculosis, but not active against other nontuberculosis mycobacteria.

Development of new anti-tuberculosis drug candidates.

TLDR
This mini-review summarizes the latest information about eight new anti-tuberculosis drug candidates and describes their activities, pharmacokinetics, mechanisms of action, and mechanisms of drug-resistance induced by these drug candidates.

Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis

TLDR
The synthesis and characterization of 1,3-benzothiazin-4-ones (BTZs), a new class of antimycobacterial agents that kill Mycobacterium tuberculosis in vitro, ex vivo, and in mouse models of TB are described.

An overview of new antitubercular drugs, drug candidates, and their targets

TLDR
Recent progress in the discovery of newly developed and Food and Drug Administration approved drugs as well as repurposed drugs, their targets, mode of action, drug‐target interactions, and their structure‐activity relationship are discussed.

Novel Inhibitors of InhA Efficiently Kill Mycobacterium tuberculosis under Aerobic and Anaerobic Conditions

TLDR
This study provides the TB drug development community with two chemical scaffolds that are suitable for structure-activity relationship study to improve on their cytotoxicities and bactericidal activities in vitro and in vivo.

Propargyl-Linked Antifolates Are Potent Inhibitors of Drug-Sensitive and Drug-Resistant Mycobacterium tuberculosis

TLDR
This work identified several PLAs as potent inhibitors of the growth of M. tuberculosis with several of the compounds exhibiting minimum inhibition concentrations equal to or less than 1 μg/mL.

Review on Tuberculosis: Trends in the Discovery of New and Efficient Chemotherapeutic Agents

TLDR
The synopsis of tuberculosis, first-lineTB drugs and their mode of action, second-line TB drugs, challenges faced with drug discovery of new TB entities and medicinal plant species are given.

Diarylcoumarins inhibit mycolic acid biosynthesis and kill Mycobacterium tuberculosis by targeting FadD32

TLDR
This work describes the identification of a 4,6-diaryl-5,7-dimethyl coumarin series that kills M. tuberculosis by inhibiting fatty acid degradation protein D32 (FadD32), an enzyme that is required for biosynthesis of cell-wall mycolic acids.
...

References

SHOWING 1-10 OF 25 REFERENCES

In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis

TLDR
The data indicate that the 5-nitroimidazole CGI 17341 is a promising and novel antituberculosis compound with potent in vitro and in vivo activities.

Bioluminescence screening in vitro (Bio-Siv) assays for high-volume antimycobacterial drug discovery

TLDR
Assay methodology has been optimized for the analysis of large numbers of novel compounds and is simple, inexpensive, and labor efficient and evidence suggests that the BCG-based screen may allow the direct identification of bactericidal agents.

Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence

TLDR
The complete genome sequence of the best-characterized strain of Mycobacterium tuberculosis, H37Rv, has been determined and analysed in order to improve the understanding of the biology of this slow-growing pathogen and to help the conception of new prophylactic and therapeutic interventions.

Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis

TLDR
Findings suggest that incubation under conditions in which oxygen is depleted gradually causes M. tuberculosis to shift down from active replication to dormancy, and the lethal effect of metronidazole under anaerobic conditions is enhanced by rifampin.

A common mechanism for the biosynthesis of methoxy and cyclopropyl mycolic acids in Mycobacterium tuberculosis.

  • Y. YuanC. Barry
  • Chemistry, Biology
    Proceedings of the National Academy of Sciences of the United States of America
  • 1996
TLDR
The similarity of these reactions and the enzymes that catalyze them suggests that some of the structural diversity of mycolic acids results from different chemical fates of a common cationic intermediate, which in turn results from methyl group addition to an olefinic mycolate precursor.

Luciferase in vivo expression technology: use of recombinant mycobacterial reporter strains to evaluate antimycobacterial activity in mice

TLDR
The use of luciferase in vivo expression for the in vivo evaluation of antimycobacterial activity compared favorably with standard CFU determinations in terms of time, labor, expense, and statistical significance but permitted the evaluation of antibacterial drugs and immunity in mice in 7 days or less.

The effect of oxygenated mycolic acid composition on cell wall function and macrophage growth in Mycobacterium tuberculosis

TLDR
A critical role for mycolate composition in proper cell wall function during the growth of MTB in vivo is established, and a substantial increase in ketomycolate and alphamycolate synthesized by intracellularly grown mycobacteria is revealed.

Structural alterations that differentially affect the mutagenic and antitrichomonal activities of 5-nitroimidazoles.

TLDR
Two approaches have been used to develop nonmutagenic 5-nitroimidazoles and in certain cases, mutagenicity was dramatically reduced while moderate antitrichomonal activity was retained.